News Sentiment

PDSB sentiment intelligence

PDS Biotechnology Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.77 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.3% over one week, -26.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction -9.3% Price reacting lower
Trend fit Trend inactive -26.3% over four weeks
Fair value -69.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 37
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 8
Stock Titan 6
Quiver Quantitative 4
simplywall.st 3
Zacks Investment Research 2
Quantisnow 1
TradingKey 1

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 20
Analyst action 4
Deals and strategy 1
Guidance 1
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Stock Titan Direct company coverage

PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal

PDS Biotechnology (NASDAQ: PDSB) has filed a resale registration for up to 13,315,823 shares of common stock for YA II PN, Ltd. These shares are related to a $6,000,000 promissory note and a warrant issued in a private placement. The company will not receive proceeds from the res

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 20:39
Source
Stock Titan
Quiver Quantitative Direct company coverage

PDSB | PDS Biotechnology Corporation Common Executive Compensation

This page provides an overview of PDS Biotechnology Corporation (PDSB), including executive compensation, congressional stock trading, insider trading, institutional holdings, and patent information. It also details the company's profile, financial data, and analyst ratings, alon

Tone
Neutral 50/100
Event
Analyst action
Published
28 Jun 2026 10:09
Source
Quiver Quantitative
TradingView Direct company coverage

Enterprise value to revenue forward of PDS Biotechnology Corporation – BOATS:PDSB

This article provides a brief financial overview for PDS Biotechnology Corporation (BOATS:PDSB) on its Enterprise Value to Revenue Forward metric. It indicates that the market was closed with no trades, and the content is primarily a data placeholder from TradingView. The article

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 03:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of PDS Biotechnology Corporation – NASDAQ:PDSB

This article provides the "Price to earnings forward" data for PDS Biotechnology Corporation (NASDAQ: PDSB). It indicates that the market was closed with no trades at the time of the report. The data originates from ICE Data Services and FactSet, with copyright held by FactSet Re

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 03:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of PDS Biotechnology Corporation – NASDAQ:PDSB

This article provides financial information for PDS Biotechnology Corporation (NASDAQ: PDSB), specifically highlighting its Enterprise Value to EBIT (forward) metric. The content focuses on presenting a data point for the company's financial analysis, indicating that this particu

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:37
Source
TradingView
TradingView Direct company coverage

Price to book forward of PDS Biotechnology Corporation – BOATS:PDSB

This page provides financial information for PDS Biotechnology Corporation (PDSB) through the Blue Ocean Alternative Trade System (BOATS) on TradingView. It specifically highlights the "Price to book forward" metric, indicating it's a financial data point for the company. The con

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 13:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of PDS Biotechnology Corporation – NASDAQ:PDSB

This article focuses on the enterprise value to revenue forward metric for PDS Biotechnology Corporation (NASDAQ: PDSB). It appears to be a financial data snippet from TradingView, providing an overview of the company's financial performance. The content includes basic company in

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 10:09
Source
TradingView
Quantisnow Direct company coverage

SEC Form DEFA14A filed by PDS Biotechnology Corporation

Quantisnow reported that PDS Biotechnology Corporation filed an SEC Form DEFA14A. The alert was sent to Quantisnow Plus members shortly after publication. Quantisnow provides real-time market data and news for retail investors, including SEC filings, FDA approvals, analyst rating

Tone
Neutral 50/100
Event
Analyst action
Published
27 Jun 2026 03:09
Source
Quantisnow
Stock Titan Direct company coverage

PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay

PDS Biotechnology (NASDAQ: PDSB) has released details for its 2026 virtual annual meeting scheduled for August 10, 2026, at 8 a.m. Eastern Time. Stockholders as of June 15, 2026, will vote on director elections, an increase in authorized common shares, auditor ratification, and e

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB)

This article provides an overview of PDS Biotechnology Corporation (PDSB) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the company's recent earnings report, revenue, market capitalization, and upcoming earnings d

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

PDSB Forecast — Price Target — Prediction for 2027

PDS Biotechnology Corporation (PDSB) stock is currently trading at $0.8940, having decreased by 4.19% in the past 24 hours. Analysts provide a wide forecast range for PDSB, with a maximum estimate of $15.00 and a minimum estimate of $3.00. The company's market capitalization is $

Tone
Neutral 50/100
Event
Guidance
Published
25 Jun 2026 14:40
Source
TradingView
Stock Titan Direct company coverage

PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program

PDS Biotechnology (NASDAQ: PDSB) has secured new financing, closing a $6 million promissory note with YA II PN, Ltd., sold for $5.76 million, and issuing a warrant for 2,158,274 common shares at $1.1824 each. Concurrently, PDSB established a $50 million "at-the-market" stock offe

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff

PDS Biotechnology (PDSB) has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026. Due to this date being more than 30 days after the anniversary of the 2025 meeting, the company has set a special deadline of June 25, 2026, for stockholder proposals to be include

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 11:39
Source
Stock Titan
Zacks Investment Research Direct company coverage

Should I buy PDS Biotechnology (PDSB)

Tone
Positive 66/100
Event
Market update
Published
10 Jun 2026 07:00
Source
Zacks Investment Research
MLQ.ai Direct company coverage

PDS Biotechnology Corporation Analyst Forecast (PDSB)

PDS Biotechnology Corporation (PDSB) currently has a consensus "Buy" rating from 7 analysts, with an average 12-month price target of $9.00, representing a significant potential upside of 782.4% from its current price of $1.02. Forecasts for the company project revenue growth and

Tone
Positive 70/100
Event
Analyst action
Published
07 Jun 2026 08:10
Source
MLQ.ai
The Globe and Mail Direct company coverage

PDS Biotechnology Regains Nasdaq Compliance, Listing Risk Removed

PDS Biotechnology (PDSB) has successfully regained compliance with Nasdaq's minimum bid price requirement, removing the immediate threat to its listing status. This resolution enhances investor confidence and trading liquidity, and ensures the biotech company's continued access t

Tone
Positive 71/100
Event
Balance sheet
Published
06 Jun 2026 23:39
Source
The Globe and Mail
Finviz Direct company coverage

PDSB - PDS Biotechnology Corp Stock Price and Quote

This article provides comprehensive stock information for PDS Biotechnology Corp (PDSB), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and press releases. It details the company's focus on developing immunotherapies

Tone
Neutral 50/100
Event
Analyst action
Published
04 Jun 2026 17:39
Source
Finviz
Stock Titan Direct company coverage

PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule

PDS Biotechnology (NASDAQ: PDSB) has announced that it has regained compliance with the Nasdaq Capital Market's minimum $1.00 bid price requirement. The company had previously received a deficiency notice in February 2026 after its stock traded below $1.00 for 30 consecutive busi

Tone
Positive 64/100
Event
Market update
Published
02 Jun 2026 19:39
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in PDS Biotechnology Corp. Stocks

This article lists ETFs that hold PDS Biotechnology Corp. (PDSB) stocks, providing details such as market value, weight, issuer, and expense ratio for each ETF. It highlights how ETFs can make investing in such stocks more accessible while offering diversification and lower risk.

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 11:39
Source
TradingView
TradingView Direct company coverage

Number of shareholders of PDS Biotechnology Corp. – SWB:EU6

This article provides metadata regarding the number of shareholders for PDS Biotechnology Corp., trading under the symbol SWB:EU6 on the Stuttgart Stock Exchange. It indicates market status, and references data from ICE Data Services, FactSet, and Quartr for financial, reference,

Tone
Neutral 50/100
Event
Market update
Published
16 May 2026 21:40
Source
TradingView
Sahm Direct company coverage

PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript

PDS Biotechnology reported a net loss of $7.3 million for Q1 2026, an improvement from the previous year, driven by reduced R&D and administrative expenses. The company advanced its clinical programs, including amending the Versatile 003 trial to potentially accelerate approval f

Tone
Positive 74/100
Event
Earnings
Published
14 May 2026 10:39
Source
Sahm